Marshall Wace’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$546K Sell
1,100
-3,400
-76% -$1.51M ﹤0.01% 2479
2026
Q1
$2.01M Buy
4,500
+4,100
+1,025% +$1.91M ﹤0.01% 1787
2025
Q4
$181K Buy
400
+200
+100% +$86.2K ﹤0.01% 2613
2025
Q3
$78.3K Buy
+200
New +$83.6K ﹤0.01% 2687

Other funds holding VRTX

Marshall Wace's VRTX Position: Q2 2026 in Review

Marshall Wace increased its Vertex Pharmaceuticals (VRTX) stake by 72% in Q2 2026, buying an estimated $101M and bringing the position to 543,897 shares worth $270M. The position accounts for 0.21% of the portfolio, ranked #64.

Marshall Wace first reported a position in VRTX in Q2 2014 and has held it in 42 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Marshall Wace held 543,897 shares of Vertex Pharmaceuticals worth $270M as of Q2 2026.
  • Marshall Wace bought 226,839 Vertex Pharmaceuticals shares in Q2 2026, an estimated $101M.
  • Vertex Pharmaceuticals made up 0.21% of Marshall Wace's portfolio in Q2 2026, its #64 holding.
  • Marshall Wace first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.